Ann: NTCELL Parkinsons trial 2 year data analysis shows success, page-48

Jeffries 2 - I agree the chart needs more labelling. I have always felt they should also show the expected line of average degradation in this index ie average expected deterioration in function which would have been based on very large patient samples over the years that they do quote in past presentations. It would highlight that just halting progression is success- improvement is added bonus. Never get a response from the company as to why they don't reflect this. it would help highlight that this trial placebo responses are/ were outliers to the normal.